Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials

Eduardo Rego • 6 Sep 2024
SOHO 2024
Acute Lymphoblastic Leukemia Leukemia

Eduardo Rego, MD, University of São Paulo, São Paulo, Brazil, discusses the efficacy of PIP4K2 inhibitors in acute lymphoblastic leukemia (ALL), specifically noting the therapy’s effectiveness against T-cell ALL (T-ALL). Dr Rego looks forward to first-in-human trials with this treatment. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eduardo Rego

The global expansion of modern AML therapy through the International Consortium on Acute Leukemia
2:44
The global expansion of modern AML therapy through the International Consortium on Acute Leukemia
Eduardo Rego • 6 Sep 2024
The management of Ph+ ALL in resource-constrained settings in South America
1:03
The management of Ph+ ALL in resource-constrained settings in South America
Eduardo Rego • 6 Sep 2024
The main challenges facing practitioners treating APL
0:56
The main challenges facing practitioners treating APL
Eduardo Rego • 18 Apr 2016
Current research on coagulopathy in APL
1:31
Current research on coagulopathy in APL
Eduardo Rego • 19 Apr 2016

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals